

SAFETY DATA SHEET

Products Containing Dako Antibody Diluent

Section 1. Identification

1.1 Product identifier

Product name : Products Containing Dako Antibody Diluent

Part no. : M0613, M0616, M0701, M0702, M0718, M0725, M0734, M0736, M0737, M0742, M0744, M0746, M0747, M0750, M0751, M0752, M0753, M0754, M0755, M0757, M0758, M0759, M0760, M0761, M0762, M0775, M0777, M0781, M0784, M0785, M0786, M0792, M0804, M0814, M0819, M0820, M0821, M0823, M0825, M0846, M0851, M0854, M0857, M0869, M0872, M0873, M0874, M0876, M0879, M0880, M0887, M0888, M0897, M3652, M7001, M7002, M7003, M7010, M7018, M7046, M7050, M7052, M7064, M7072, M7077, M7082, M7103, M7157, M7158, M7165, M7195, M7196, M7202, M7203, M7211, M7228, M7245, M7254, M7255, M7259, M7260, M7273, M7257, M7279, M7296, M7297, M7298, M7304, M7307, M7312, M7313, M7315, M7316, M7317, X0931, X0942, X0943, X0944

Validation date : 3/8/2022

1.2 Relevant identified uses of the substance or mixture and uses advised against

Material uses : Laboratory use

Container type: Bottle

M0613 // Monoclonal Mouse Anti-Human Epithelial Membrane Antigen, Clone E29 // 0.2 ml, 1 ml

M0616 // Monoclonal Mouse Anti-Human Von Willebrand Factor, Clone F8 // 86 // 1 ml

M0701 // Monoclonal Mouse Anti-Human CD45, Leucocyte Common Antigen, Clones 2B11 + PD7 // 26 // 0.2 ml, 1 ml

M0702 // Monoclonal Mouse Anti-Human Immunoglobulin M // 50 mL - 3L

M0718 // Monoclonal Mouse Anti-Human CD68, Clone EBM11 // 1 ml

M0725 // Monoclonal Mouse Anti-Vimentin, Clone V9 // 0.2 ml, 1 ml

M0734 // Monoclonal Mouse Anti-Human Transferrin Receptor, CD71, Clone Ber-T9 // 50 mL - 3L

M0736 // Monoclonal Mouse Anti-Human HLA-ABC Antigen, Clone W6 // 32 // 1 ml

M0737 // Monoclonal Mouse Anti-Rabbit Immunoglobulins, Clone MR12 // 53 // 1 ml

M0742 // Monoclonal Mouse Anti-Human CD45R0, Clone UCHL1 // 1 ml

M0744 // Monoclonal Mouse Anti-Bromodeoxyuridine, Clone Bu20a // 1 ml

M0746 // Monoclonal Mouse Anti-Human HLA-DR Antigen, Alpha-Chain, Clone TAL.1B5 // 1 ml

M0747 // Monoclonal Mouse Anti-Human Myeloid // Histiocyte Antigen, Clone MAC 387 // 1 ml

M0750 // Monoclonal Mouse Anti-Human Prostate-Specific Antigen, Clone ER-PR8 // 0.2 ml

M0751 // Monoclonal Mouse Anti-Human CD30, Clone Ber-H2 // 0.2 ml, 1 ml

M0752 // Monoclonal Mouse Anti-Human Neutrophil Elastase, Clone NP57 // 1 ml

M0753 // Monoclonal Mouse Anti-Human CD61, Platelet Glycoprotein IIIa, Clone Y2 // 51 // 1 ml

M0754 // Monoclonal Mouse Anti-Human CD45RA, Clone 4KB5 // 1 ml

M0755 // Monoclonal Mouse Anti-Human CD20cy, Clone L26 // 0.2 ml, 1 ml

M0757 // Monoclonal Mouse Anti-Cytomegalovirus, Clone CCH2 // 50 mL - 3 L

M0758 // Monoclonal Mouse Anti-Human Serotonin, Clone 5HT-H209 // 1 ml

M0759 // Monoclonal Mouse Anti-Human Amyloid A, Clone mc1 // 1 ml, 2 mL - 3 L

M0760 // Monoclonal Mouse Anti-Human Desmin, Clone D33 // 0.2 ml, 1 ml

M0761 // Monoclonal Mouse Anti-Human Glial Fibrillary Acidic Protein, Clone 6F2 // 1 ml

M0762 // Monoclonal Mouse Anti-Human Neurofilament Protein, Clone 2F11 // 0.2 ml

M0775 // Monoclonal Mouse Anti-Human HLA-DP, DQ, DR Antigen, Clone CR3 // 43 // 1 ml

M0777 // Monoclonal Mouse Anti-Human C5b-9, Clone aE11 // 1 ml

M0781 // Monoclonal Mouse Anti-Human Thyroglobulin, Clone DAK-Tg6 // 1 ml

M0784 // Monoclonal Mouse Anti-Human CD21, Clone 1F8 // 1 ml

M0785 // Monoclonal Mouse Anti-Human Collagen IV, Clone CIV 22 // 1 ml

M0786 // Monoclonal Mouse Anti-Human CD43, Clone DF-T1 // 1 ml

M0792 // Monoclonal Mouse Anti-Human Prostatic Acid Phosphatase, Clone PASE // 4LJ // 1 ml

M0804 // Monoclonal Mouse Anti-Human Epithelial Antigen, Clone Ber-EP4 // 0.2 ml, 1 ml

M0814 // Monoclonal Mouse Anti-Human CD68, Clone KP1 // 1 ml

Section 1. Identification

M0819 // Monoclonal Mouse Anti-Human CD235a, Glycophorin A, Clone JC159 // 1 ml
 M0820 // Monoclonal Mouse Anti-Human Glycophorin C, Clone Ret40f // 1 ml
 M0821 // Monoclonal Mouse Anti-Human Cytokeratin, Clone MNF116 // 1 ml
 M0823 // Monoclonal Mouse Anti-Human CD31, Endothelial Cell, Clone JC70A // 0.2 ml, 1 ml
 M0825 // Monoclonal Mouse Anti-Human CD14, Clone TÜK4 // 1 ml
 M0846 // Monoclonal Mouse Anti-Human CD35, Clone Ber-MAC-DRC // 1 ml
 M0851 // Monoclonal Mouse Anti-Human Smooth Muscle Actin, Clone 1A4 // 0.2 ml, 1 ml
 M0854 // Monoclonal Mouse Anti-Cytomegalovirus, Clones CCH2 + DDG9 // 1 ml, 50 mL - 3L
 M0857 // Monoclonal Mouse Anti-Human Immunodeficiency Virus, p24, Clone Kal-1 // 1 ml
 M0869 // Monoclonal Mouse Anti-Human ChromoGrannin A, Clone DAK-A3 // 0.2 ml, 1 ml, 2 mL - 3 L
 M0872 // Monoclonal Mouse Anti-Human Beta-Amyloid, Clone 6F // 3D // 1 ml, 2 mL -3 L
 M0873 // Monoclonal Mouse Anti-Human Neuron-Specific Enolase, Clone BBS // NC // VI-H14 // 0.2 ml, 1 ml
 M0874 // Monoclonal Mouse Anti-Sarcomeric Actin, Clone Alpha-Sr-1 // 1 ml
 M0876 // Monoclonal Mouse Anti-Human CD68, Clone PG-M1 // 0.2 ml, 1 ml
 M0879 // Monoclonal Mouse Anti-Proliferating Cell Nuclear Antigen, Clone PC10 // 1 ml
 M0880 // Monoclonal Mouse Anti-Human Leukaemia, Hairy Cell, Clone DBA.44 // 1 ml
 M0887 // Monoclonal Mouse Anti-Human BCL2 Oncoprotein, Clone 124 // 0.2 ml, 1 ml
 M0888 // Monoclonal Mouse Anti-Human Cytokeratin 19, Clone RCK108 // 1 ml
 M0897 // Monoclonal Mouse Anti-Epstein-Barr Virus, LMP, Clones CS.1-4 // 2 mL - 3 L
 M3652 // Monoclonal Rabbit Anti-Human Cytokeratin 8 // 18, Clone EP17 // EP30 // 1 ml
 M7001 // Monoclonal Mouse Anti-Human p53 Protein, Clone DO-7 // 0.2 ml, 1 ml
 M7002 // Monoclonal Mouse Anti-Human Cytokeratin 10, Clone DE-K10 // 1 ml
 M7003 // Monoclonal Mouse Anti-Human Cytokeratin 10 // 13, Clone DE-K13 // 1 ml
 M7010 // Monoclonal Mouse Anti-Human Cytokeratin 18, Clone DC 10 // 0.2 ml
 M7018 // Monoclonal Mouse Anti-Human Cytokeratin 7, Clone OV-TL 12 // 30 // 0.2 ml, 1 ml
 M7046 // Monoclonal Mouse Anti-Cytokeratin 17, Clone E3 // 1 ml
 M7050 // Monoclonal Mouse Anti-Human CD79 α , Clone JCB117 // 0.2 ml, 1 ml
 M7052 // Monoclonal Mouse Anti-Human Mast Cell Tryptase, Clone AA1 // 0.2 ml
 M7064 // Monoclonal Mouse Anti-Enterovirus, Clone 5-D8 // 1 // 1 ml
 M7072 // Monoclonal Mouse Anti-Human Carcinoembryonic Antigen, Clone II-7 // 0.2 ml, 1 ml
 M7077 // Monoclonal Mouse Anti-Human Plasma Cell, Clone VS38c // 1 ml
 M7082 // Monoclonal Mouse Anti-Human CD44, Phagocytic Glycoprotein-1, Clone DF1485 // 1 ml
 M7103 // Monoclonal Mouse Anti-Human CD8, Clone C8 // 144B // 1 ml
 M7157 // Monoclonal Mouse Anti-Human Follicular Dendritic Cell, Clone CNA.42 // 1 ml
 M7158 // Monoclonal Mouse Anti-Human Hepatocyte, Clone OCH1E5 // 1 ml
 M7165 // Monoclonal Mouse Anti-Human CD34 Class II, Clone QBEnd 10 // 0.2 ml, 1 ml
 M7195 // Monoclonal Mouse Anti-Human CD246, ALK Protein, Clone ALK1 // 0.2 ml, 1 ml
 M7196 // Monoclonal Mouse Anti-Human Melan-A, Clone A103 // 0.2 ml, 1 ml
 M7202 // Monoclonal Mouse Anti-Human p21WAF1 // Cip1, Clone SX118 // 0.2 ml
 M7203 // Monoclonal Mouse Anti-Human p27Kip1, Clone SX53G8 // 1 ml
 M7211 // Monoclonal Mouse Anti-Human BCL6 Protein, Clone PG-B6p // 0.2 ml, 1 ml
 M7228 // Monoclonal Mouse Anti-Human CD138, Clone MI15 // 1 ml
 M7245 // Monoclonal Mouse Anti-Human Calretinin, Clone DAK-Calret 1 // 0.2 ml, 1 ml
 M7254 // Monoclonal Mouse Anti-Human CD3, Clone F7.2.38 // 0.2 ml, 1 ml
 M7255 // Monoclonal Mouse Anti-Human CD7, Clone CBC.37 // 1 ml
 M7257 // Monoclonal Mouse Anti-Human Thyroid Peroxidase, Clone MoAb47 // 0.2 ml
 M7259 // Monoclonal Mouse Anti-Human MUM1 Protein, Clone MUM1p // 0.2 ml, 1 ml
 M7260 // Monoclonal Mouse Anti-Human BCL10 Protein, Clone 151 // 0.2 ml
 M7273 // Monoclonal Mouse Anti-Human Vascular Endothelial Growth Factor, Clone VG1 // 0.2 ml
 M7279 // Monoclonal Mouse Anti-Human LAT Protein, Clone LAT-1 // 0.2 ml
 M7296 // Monoclonal Mouse Anti-Human CD19, Clone LE-CD19 // 0.2 ml
 M7297 // Monoclonal Mouse Anti-Human HER3, Clone DAK-H3-IC // 0.2 ml
 M7298 // Monoclonal Mouse Anti-Human Wild-Type EGFR, Clone DAK-H1-WT // 0.2 ml
 M7304 // Monoclonal Mouse Anti-Human CD56, Clone 123C3 // 0.2 ml, 1 ml
 M7307 // Monoclonal Mouse Anti-Human B-Cell-Specific Activator Protein, Clone DAK-Pax5 // 1 ml
 M7312 // Monoclonal Mouse Anti-Human CD23, Clone DAK-CD23 // 1 ml
 M7313 // Monoclonal Mouse Anti-Human MUC2, Clone CCP58 // 0.2 ml, 1 ml
 M7315 // Monoclonal Mouse Anti-Human Synaptophysin, Clone DAK-SYNAP // 0.2 ml, 1 ml
 M7316 // Monoclonal Mouse Anti-Human MUC5AC, Clone CLH2 // 0.2 ml, 1 ml

Section 1. Identification

M7317 // Monoclonal Mouse Anti-Human p63 Protein, Clone DAK-p63 // 0.2 ml, 1 ml
X0931 // Control Reagent, Mouse IgG1 // 1 ml
X0942 // Control Reagent, Mouse IgM // 1 ml
X0943 // Control Reagent, Mouse IgG2a // 1 ml
X0944 // Control Reagent, Mouse IgG2b // 1 ml
Reference number:SDS443

1.3 Details of the supplier of the safety data sheet

Supplier/Manufacturer

: Agilent Technologies, Inc.
5301 Stevens Creek Blvd
Santa Clara, CA 95051, USA
Tel: +1 800 227 9770

Agilent Technologies Singapore (International) Pte Ltd.
No. 1 Yishun Avenue 7
Singapore, 768923
Tel. (65) 6276 2622

Agilent Technologies Denmark ApS
Produktionsvej 42
2600 Glostrup,
Denmark
Tel. +45 44 85 95 00

www.Agilent.com

e-mail address of person responsible for this SDS : SDS@Agilent.com

1.4 Emergency telephone number

In case of emergency : CHEMTREC®: 1-800-424-9300

Section 2. Hazards identification

2.1 Classification of the substance or mixture

OSHA/HCS status : While this material is not considered hazardous by the OSHA Hazard Communication Standard (29 CFR 1910.1200), this SDS contains valuable information critical to the safe handling and proper use of the product. This SDS should be retained and available for employees and other users of this product.

Classification of the substance or mixture

Not classified.

2.2 GHS label elements

Signal word : No signal word.
Hazard statements : No known significant effects or critical hazards.
Precautionary statements
Prevention : Not applicable.
Response : Not applicable.
Storage : Not applicable.
Disposal : Not applicable.

2.3 Other hazards

Hazards not otherwise classified : None known.

Section 3. Composition/information on ingredients

Substance/mixture : Mixture

There are no ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified and hence require reporting in this section.

Occupational exposure limits, if available, are listed in Section 8.

Section 4. First aid measures

4.1 Description of necessary first aid measures

- Eye contact** : Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Get medical attention if irritation occurs.
- Inhalation** : Remove victim to fresh air and keep at rest in a position comfortable for breathing. Get medical attention if symptoms occur. In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours.
- Skin contact** : Flush contaminated skin with plenty of water. Remove contaminated clothing and shoes. Get medical attention if symptoms occur.
- Ingestion** : Wash out mouth with water. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Do not induce vomiting unless directed to do so by medical personnel. Get medical attention if symptoms occur.

4.2 Most important symptoms/effects, acute and delayed

Potential acute health effects

- Eye contact** : No known significant effects or critical hazards.
- Inhalation** : No known significant effects or critical hazards.
- Skin contact** : No known significant effects or critical hazards.
- Ingestion** : No known significant effects or critical hazards.

Over-exposure signs/symptoms

- Eye contact** : No specific data.
- Inhalation** : No specific data.
- Skin contact** : No specific data.
- Ingestion** : No specific data.

4.3 Indication of immediate medical attention and special treatment needed, if necessary

- Notes to physician** : In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours.
- Specific treatments** : No specific treatment.
- Protection of first-aiders** : No action shall be taken involving any personal risk or without suitable training.

See toxicological information (Section 11)

Section 5. Fire-fighting measures

5.1 Extinguishing media

- Suitable extinguishing media** : Use an extinguishing agent suitable for the surrounding fire.
- Unsuitable extinguishing media** : None known.

5.2 Special hazards arising from the substance or mixture

Section 5. Fire-fighting measures

Specific hazards arising from the chemical : In a fire or if heated, a pressure increase will occur and the container may burst.

Hazardous thermal decomposition products : Decomposition products may include the following materials:
carbon dioxide
carbon monoxide
nitrogen oxides
phosphorus oxides

5.3 Advice for firefighters

Special protective actions for fire-fighters : Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.

Special protective equipment for fire-fighters : Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode.

Section 6. Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

For non-emergency personnel : No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilled material. Put on appropriate personal protective equipment.

For emergency responders : If specialized clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".

6.2 Environmental precautions : Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).

6.3 Methods and materials for containment and cleaning up

Methods for cleaning up : Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.

Section 7. Handling and storage

7.1 Precautions for safe handling

Protective measures : Put on appropriate personal protective equipment (see Section 8).

Advice on general occupational hygiene : Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

7.2 Conditions for safe storage, including any incompatibilities : Specific storage conditions: Please consult the label.
Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabeled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

Section 7. Handling and storage

7.3 Specific end use(s)

- Recommendations** : Industrial applications, Professional applications.
Industrial sector specific solutions : Not available.

Section 8. Exposure controls/personal protection

8.1 Control parameters

Occupational exposure limits

Ingredient name	Exposure limits
None.	

8.2 Exposure controls

- Appropriate engineering controls** : Good general ventilation should be sufficient to control worker exposure to airborne contaminants.
- Environmental exposure controls** : Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

Individual protection measures

- Hygiene measures** : Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.
- Eye/face protection** : Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: safety glasses with side-shields.
- Skin protection**
- Hand protection** : Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary.
- Body protection** : Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.
- Other skin protection** : Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.
- Respiratory protection** : Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.

Section 9. Physical and chemical properties and safety characteristics

The conditions of measurement of all properties are at standard temperature and pressure unless otherwise indicated.

Appearance

Physical state	: Liquid. [Clear.]
Color	: Colorless.
Odor	: Odorless.
Odor threshold	: Not available.
pH	: 7.6
Melting point/freezing point	: 0°C (32°F)
Boiling point, initial boiling point, and boiling range	: 100°C (212°F)
Flash point	: Not available.
Evaporation rate	: Not available.
Flammability	: Not applicable.
Lower and upper explosion limit/flammability limit	: Not available.
Vapor pressure	:

Ingredient name	Vapor Pressure at 20°C			Vapor pressure at 50°C		
	mm Hg	kPa	Method	mm Hg	kPa	Method
Water	23.8	3.2		92.258	12.3	
Sodium azide	0.0075	0.001				

Relative vapor density	: Not available.
Relative density	: Not available.
Solubility	: Soluble in the following materials: cold water and hot water.
Miscible with water	: <input checked="" type="checkbox"/> Yes.
Partition coefficient: n-octanol/water	: <input checked="" type="checkbox"/> Not applicable.
Auto-ignition temperature	:

Ingredient name	°C	°F	Method
Sodium azide	309	588.2	EU A.16

Decomposition temperature	: Not available.
Viscosity	: Not available.

Particle characteristics

Median particle size	: <input checked="" type="checkbox"/> Not applicable.
-----------------------------	---

Section 10. Stability and reactivity

10.1 Reactivity	: No specific test data related to reactivity available for this product or its ingredients.
10.2 Chemical stability	: The product is stable.
10.3 Possibility of hazardous reactions	: Under normal conditions of storage and use, hazardous reactions will not occur.
10.4 Conditions to avoid	: No specific data.
10.5 Incompatible materials	: May react or be incompatible with oxidizing materials.

Section 10. Stability and reactivity

10.6 Hazardous decomposition products : Under normal conditions of storage and use, hazardous decomposition products should not be produced.

Section 11. Toxicological information

11.1 Information on toxicological effects

Acute toxicity

Not available.

Irritation/Corrosion

Not available.

Sensitization

Not available.

Mutagenicity

Conclusion/Summary : Not available.

Carcinogenicity

Conclusion/Summary : Not available.

Reproductive toxicity

Conclusion/Summary : Not available.

Teratogenicity

Conclusion/Summary : Not available.

Specific target organ toxicity (single exposure)

Not available.

Specific target organ toxicity (repeated exposure)

Not available.

Aspiration hazard

Not available.

Information on the likely routes of exposure : Not available.

Potential acute health effects

Eye contact : No known significant effects or critical hazards.

Inhalation : No known significant effects or critical hazards.

Skin contact : No known significant effects or critical hazards.

Ingestion : No known significant effects or critical hazards.

Symptoms related to the physical, chemical and toxicological characteristics

Eye contact : No specific data.

Inhalation : No specific data.

Skin contact : No specific data.

Ingestion : No specific data.

Delayed and immediate effects and also chronic effects from short and long term exposure

Short term exposure

Potential immediate effects : Not available.

Potential delayed effects : Not available.

Section 11. Toxicological information

Long term exposure

Potential immediate effects : Not available.

Potential delayed effects : Not available.

Potential chronic health effects

General : No known significant effects or critical hazards.

Carcinogenicity : No known significant effects or critical hazards.

Mutagenicity : No known significant effects or critical hazards.

Reproductive toxicity : No known significant effects or critical hazards.

Numerical measures of toxicity

Acute toxicity estimates

N/A

Section 12. Ecological information

12.1 Toxicity

Not available.

12.2 Persistence and degradability

Not available.

12.3 Bioaccumulative potential

Not available.

12.4 Mobility in soil

Soil/water partition coefficient (K_{oc}) : Not available.

12.5 Other adverse effects : No known significant effects or critical hazards.

Section 13. Disposal considerations

13.1 Waste treatment methods

Disposal methods : The generation of waste should be avoided or minimized wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible. This material and its container must be disposed of in a safe way. Empty containers or liners may retain some product residues. Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers.

Section 13. Disposal considerations

Disposal should be in accordance with applicable regional, national and local laws and regulations. Local regulations may be more stringent than regional or national requirements.

The information presented below only applies to the material as supplied. The identification based on characteristic(s) or listing may not apply if the material has been used or otherwise contaminated. It is the responsibility of the waste generator to determine the toxicity and physical properties of the material generated to determine the proper waste identification and disposal methods in compliance with applicable regulations.

Refer to Section 7: HANDLING AND STORAGE and Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION for additional handling information and protection of employees.

Section 14. Transport information

DOT / TDG / Mexico / IMDG / IATA : Not regulated.

Special precautions for user : **Transport within user's premises:** always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.

Transport in bulk according to IMO instruments : Not available.

Section 15. Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

U.S. Federal regulations : TSCA 8(a) CDR Exempt/Partial exemption: Not determined

Clean Air Act Section 112 (b) Hazardous Air Pollutants (HAPs) : Not listed

Clean Air Act Section 602 Class I Substances : Not listed

Clean Air Act Section 602 Class II Substances : Not listed

DEA List I Chemicals (Precursor Chemicals) : Not listed

DEA List II Chemicals (Essential Chemicals) : Not listed

SARA 302/304

Composition/information on ingredients

Name	%	EHS	SARA 302 TPQ		SARA 304 RQ	
			(lbs)	(gallons)	(lbs)	(gallons)
Sodium azide	<0.1	Yes.	500	-	1000	-

SARA 304 RQ : 1020408.2 lbs / 463265.3 kg

SARA 311/312

Classification : Not applicable.

Composition/information on ingredients

No products were found.

State regulations

Section 15. Regulatory information

- Massachusetts** : None of the components are listed.
New York : None of the components are listed.
New Jersey : None of the components are listed.
Pennsylvania : None of the components are listed.
California Prop. 65

This product does not require a Safe Harbor warning under California Prop. 65.

International regulations

Chemical Weapon Convention List Schedules I, II & III Chemicals

Not listed.

Montreal Protocol

Not listed.

Stockholm Convention on Persistent Organic Pollutants

Not listed.

Rotterdam Convention on Prior Informed Consent (PIC)

Not listed.

UNECE Aarhus Protocol on POPs and Heavy Metals

Not listed.

Inventory list

- Australia** : Not determined.
Canada : Not determined.
China : All components are listed or exempted.
Europe : All components are listed or exempted.
Japan : **Japan inventory (CSCL)**: Not determined.
Japan inventory (ISHL): All components are listed or exempted.
New Zealand : Not determined.
Philippines : Not determined.
Republic of Korea : Not determined.
Taiwan : Not determined.
Thailand : Not determined.
Turkey : Not determined.
United States : All components are active or exempted.
Viet Nam : Not determined.

Section 16. Other information

Procedure used to derive the classification

Classification	Justification
Not classified.	

History

- Date of issue** : 03/08/2022
Date of previous issue : 05/31/2020
Version : 3

Section 16. Other information

Key to abbreviations

- : ATE = Acute Toxicity Estimate
- BCF = Bioconcentration Factor
- GHS = Globally Harmonized System of Classification and Labelling of Chemicals
- IATA = International Air Transport Association
- IBC = Intermediate Bulk Container
- IMDG = International Maritime Dangerous Goods
- LogPow = logarithm of the octanol/water partition coefficient
- MARPOL = International Convention for the Prevention of Pollution From Ships, 1973 as modified by the Protocol of 1978. ("Marpol" = marine pollution)
- N/A = Not available
- UN = United Nations

✔ Indicates information that has changed from previously issued version.

Notice to reader

Disclaimer: The information contained in this document is based on Agilent's state of knowledge at the time of preparation. No warranty as to its accurateness, completeness or suitability for a particular purpose is expressed or implied.